Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

October 6, 2025

Biodexa to Host Breakfast Symposium on

FAP Mechanisms and Chemoprevention Trial Issues

at CGA – IGC Conference on October 11, 2025

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, will host a breakfast symposium at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) annual meeting in St Louis, MO on October 9-11, 2025.

The symposium presentation, titled “FAP mechanisms and Chemoprevention Trial Issues” will be delivered by guest speaker Dr Patrick Lynch MD, Professor of Medicine (Rtd), Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center. After the presentation there will be an interactive panel discussion with panellists Sonia S. Kupfer MD, Professor of Medicine, University of Chicago and Paul E. Wise MD, Professor of Surgery, Washington University.

"We are honored to convene this distinguished panel at such a prestigious scientific forum," said Dr. Gary Shangold, Chief Medical Officer of Biodexa. "This symposium reflects the collaborative nature of our research approach and the significant scientific and clinical interest in advancing FAP treatment options. The insights shared will be invaluable as we continue to advance our Phase 3 Serenta trial and work toward potentially providing the first approved therapy for FAP patients."

The symposium takes place during a pivotal period for Biodexa's FAP program, as the company advances its Phase 3 Serenta trial of eRapa, a proprietary oral formulation of rapamycin. The trial represents a significant opportunity to address the substantial unmet medical need in FAP, where patients currently face limited options beyond surgical intervention. Several conference attendees are actively collaborating as clinical investigators in the ongoing Phase 3 study, highlighting the scientific interest in this therapeutic approach.

ENDS

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.